Main image Main image

Cend Therapeutics In The News

October 26, 2019

La Jolla, CA – DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing novel treatment approaches to overcome the barriers of drug delivery in solid tumors, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent related to CendR peptides, further strengthening the company’s intellectual property portfolio beyond the already granted composition of matter patents. U.S. Patent No. 10370245B2 (‘Methods and compositions related to peptides and proteins with c-terminal elements’) has 183 claims and an adjusted expiry in November 2030. The patent is already active in Europe, Japan and China.

“This new patent that provides broad coverage on all peptides with CendR element ensures a robust intellectual property position around the CEND-1 platform technology and the claims granted in this particular patent exemplify the novel mechanistic approach of our science” said Harri Jarvelainen, Chief Operating Officer of DrugCendR Inc. “This development becomes more and more important as we progress with our clinical trial in patients with metastatic pancreatic cancer and prepare to publish the results at a major upcoming scientific meeting next year”.

For more information.



INNOVATION Kyoto 2016 LPs Completes Strategic Investment in DrugCendR Inc.

(Kyoto, Japan / La Jolla, CA) – INNOVATION Kyoto 2016 Limited Liability Partnership (“KYOTO-iCAP 1st Fund”), and Kyoto University Innovation Capital Co., Ltd. (the general partner. Headquarters: Sakyo-ku, Kyoto City; CEO: Koji Murota; “Kyoto-iCAP”) and DrugCendR Inc. (Headquarters: La Jolla, CA, US; President and CEO: Erkki Ruoslahti; “DrugCendR”) today jointly announced that it has concluded a multimillion-dollar investment in DrugCendR, to accelerate the global development of DrugCendR’s breakthrough tumor penetrating technology.

“I am delighted to announce the completion of the strategic investment in DrugCendR Inc. We, Kyoto-iCAP, will continue to support the development of DrugCendR’s technologies in the long term.”said Koji Murota, CEO of Kyoto-iCAP.

“This investment into DrugCendR Inc. by Kyoto-iCAP and Kyoto University will allow us to complete our ongoing phase 1 clinical trial on the lead compound of the company” stated Dr. Erkki Ruoslahti, M.D., Ph.D., President and CEO of DrugCendR. “The strategic relationship with the fund and Kyoto University, a preeminent university in the world, will be important for us into the future. We will also collaborate with clinical researchers led by Dr. Yoshiharu Sakai, M.D., Ph.D., Professor of Surgery on clinical studies the university is uniquely equipped to perform. We hope to provide new treatment options for cancer patients in the US, Japan and elsewhere in the world.”

Concurrent with the investment, DrugCendR will initiate non-clinical and clinical research collaboration with Kyoto University. Professor Yoshiharu Sakai, M.D., Ph.D., Gastrointestinal Surgery, Department of Surgery, Kyoto University and Associate Professor Kazutaka Obama, M.D., Ph.D. will lead the collaboration for Kyoto University.